Form 4: Twist Bioscience COO Awarded 68,740 Restricted Stock Units

Patrick John Finn, President and COO of Twist Bioscience Corp, received a restricted stock unit award of 68,740 shares.

Summary

• Patrick John Finn, President and COO of Twist Bioscience Corp (TWST), was granted 68,740 shares of Common Stock as a Restricted Stock Unit (RSU) award.
• The transaction date for this acquisition was November 18, 2025.
• The RSUs were acquired at a price of $0, which is typical for such awards.
• Following this transaction, Mr. Finn beneficially owns 334,659 shares of Common Stock.
• The RSU award vests over 48 months, with 1/16th of the total number of RSUs vesting on each quarterly anniversary of November 20, 2025.
• Vesting is contingent upon Mr. Finn's continuous service through each vesting date.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event (RSU award) which is generally positive for executive retention and alignment, but does not contain information that would significantly alter the company's fundamental outlook or financial position.

Positives

• The RSU award serves as an incentive for the President and COO, aligning his long-term interests with those of the shareholders.
• The award demonstrates the company's commitment to retaining and motivating key executive talent.

Negatives

• The award has no immediate cash value to the recipient and is subject to a multi-year vesting schedule.
• The shares are not fully owned until all vesting conditions are met, specifically continuous service.

Risks

• The reporting person risks forfeiture of unvested RSUs if their continuous service with the company terminates before the vesting dates.
• The value of the award is subject to the future performance and market price of Twist Bioscience Corp's common stock.

Future Outlook

The vesting schedule of the RSU award, extending over 48 months, indicates an expectation of continued service from the President and COO, aligning his incentives with the company's long-term performance.

Industry Context

The granting of Restricted Stock Units (RSUs) is a common form of executive compensation in the biotechnology and life sciences industry, used to attract, retain, and incentivize key management by aligning their interests with long-term shareholder value creation.

Comparison to Industry Standards

• RSU awards with multi-year vesting schedules are a standard practice for executive compensation across technology and biotech sectors, comparable to practices at companies like Illumina or Thermo Fisher Scientific, which also utilize equity-based incentives to retain top talent.
• The 'zero price' acquisition is typical for RSU grants, where the value is derived from the underlying stock price at vesting, a common structure seen in compensation plans for executives at peer companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The award aligns executive incentives with shareholder interests over the long term, though it represents potential future dilution upon vesting.
• Employees: May signal stability in executive leadership and a commitment to performance-based compensation.

Next Steps

• The RSUs will begin vesting on a quarterly basis starting November 20, 2025, over a 48-month period, subject to continuous service.

Key Dates

Keywords

Twist Bioscience, TWST, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Beneficial Ownership, Patrick John Finn